Birchview Capital’s Neurocrine Biosciences NBIX Stock Holding History

Birchview Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.58M	Hold	27,190	–	–	2.04%	14
2025 Q4	$3.86M	Sell	27,190 -1,500	-5%	-$217K	2.26%	13
2025 Q3	$4.03M	Sell	28,690 -2,250	-7%	-$305K	3.04%	8
2025 Q2	$3.89M	Buy	30,940 +700	+2%	+$80.3K	3.86%	6
2025 Q1	$3.34M	Hold	30,240	–	–	2.9%	6
2024 Q4	$4.13M	Hold	30,240	–	–	3.36%	6
2024 Q3	$3.48M	Sell	30,240 -12,000	-28%	-$1.65M	3.02%	7
2024 Q2	$5.82M	Sell	42,240 -35,000	-45%	-$4.8M	5.37%	4
2024 Q1	$10.7M	Hold	77,240	–	–	8.68%	2
2023 Q4	$10.2M	Hold	77,240	–	–	7.96%	2
2023 Q3	$8.69M	Sell	77,240 -7,000	-8%	-$737K	7.38%	3
2023 Q2	$7.94M	Hold	84,240	–	–	5.95%	3
2023 Q1	$8.53M	Hold	84,240	–	–	6.68%	3
2022 Q4	$10.1M	Sell	84,240 -1,000	-1%	-$117K	7.11%	3
2022 Q3	$9.05M	Hold	85,240	–	–	6.37%	3
2022 Q2	$8.31M	Sell	85,240 -4,000	-4%	-$369K	6.04%	3
2022 Q1	$8.37M	Buy	89,240 +40	+0%	+$3.39K	6.02%	2
2021 Q4	$7.6M	Buy	89,200 +9,000	+11%	+$828K	4.9%	5
2021 Q3	$7.69M	Hold	80,200	–	–	5.23%	5
2021 Q2	$7.8M	Hold	80,200	–	–	4.67%	4
2021 Q1	$7.8M	Hold	80,200	–	–	4.63%	4
2020 Q4	$7.69M	Buy	80,200 +2,200	+3%	+$212K	4.43%	5
2020 Q3	$7.5M	Hold	78,000	–	–	5.01%	5
2020 Q2	$9.52M	Buy	78,000 +4,000	+5%	+$442K	5.75%	5
2020 Q1	$6.41M	Buy	74,000 +19,000	+35%	+$1.86M	5.68%	3
2019 Q4	$5.91M	Hold	55,000	–	–	4.3%	3
2019 Q3	$4.96M	Hold	55,000	–	–	3.3%	3
2019 Q2	$4.64M	Hold	55,000	–	–	2.82%	4
2019 Q1	$4.85M	Hold	55,000	–	–	3.04%	4
2018 Q4	$3.93M	Buy	55,000 +7,000	+15%	+$671K	3.72%	3
2018 Q3	$5.9M	Sell	48,000 -2,000	-4%	-$227K	3.81%	3
2018 Q2	$4.91M	Sell	50,000 -2,400	-5%	-$215K	3.34%	3
2018 Q1	$4.35M	Hold	52,400	–	–	2.86%	3
2017 Q4	$4.07M	Hold	52,400	–	–	2.38%	4
2017 Q3	$3.21M	Buy	52,400 +27,200	+108%	+$1.44M	1.66%	4
2017 Q2	$1.16M	Hold	25,200	–	–	0.61%	7
2017 Q1	$1.09M	Hold	25,200	–	–	0.61%	10
2016 Q4	$975K	Hold	25,200	–	–	0.6%	11
2016 Q3	$1.28M	Hold	25,200	–	–	0.74%	9
2016 Q2	$1.15M	Hold	25,200	–	–	0.83%	10
2016 Q1	$997K	Buy	25,200 +2,000	+9%	+$79.4K	0.71%	11
2015 Q4	$1.31M	Buy	23,200 +13,500	+139%	+$686K	0.76%	11
2015 Q3	$386K	Buy	+9,700	New	+$469K	0.25%	26

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Birchview Capital's NBIX Position: Q1 2026 in Review

Birchview Capital held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 27,190 shares worth $3.58M. The position accounts for 2.04% of the portfolio, ranked #14.

Birchview Capital first reported a position in NBIX in Q3 2015 and has held it in 43 quarters since. The position peaked at $10.7M in Q1 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Birchview Capital held 27,190 shares of Neurocrine Biosciences worth $3.58M as of Q1 2026.
Birchview Capital left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up 2.04% of Birchview Capital's portfolio in Q1 2026, its #14 holding.
Birchview Capital first reported a position in Neurocrine Biosciences in Q3 2015 and has held it in 43 quarters since.
Birchview Capital's Neurocrine Biosciences position peaked at $10.7M in Q1 2024.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.